| Literature DB >> 30794296 |
Sara R Piva1, Michael J Schneider1, Charity G Moore1, M Beatriz Catelani1, Alexandra B Gil1, Brian A Klatt2, Anthony M DiGioia3, Gustavo J Almeida1, Samannaaz S Khoja1, Gwendolyn Sowa4, James J Irrgang1.
Abstract
Importance: Several functional limitations persist after total knee replacement (TKR). Intensive exercise programs could resolve these limitations but are not well tolerated by many patients until a later stage (>2 months) after surgery. Evidence for exercise at a later stage after TKR is limited.Entities:
Mesh:
Year: 2019 PMID: 30794296 PMCID: PMC6484600 DOI: 10.1001/jamanetworkopen.2019.0018
Source DB: PubMed Journal: JAMA Netw Open ISSN: 2574-3805
Figure 1. Consolidated Standards of Reporting Trials (CONSORT) Diagram of Participant Flow During the Study
TKR indicates total knee replacement; WOMAC-PF, Western Ontario and McMaster Universities Osteoarthritis Index–Physical Function.
Participant Characteristics at Baseline
| Variable | Physical Therapy (n = 96) | Community (n = 96) | Control (n = 48) |
|---|---|---|---|
| Age, mean (SD), y | 69 (6) | 70 (7) | 70 (7) |
| Female, No. (%) | 59 (61.5) | 58 (60.4) | 31 (64.6) |
| Race, No. (%) | |||
| White | 86 (89.6) | 77 (80.2) | 37 (77.1) |
| African American | 10 (10.4) | 18 (18.8) | 11 (22.9) |
| American Indian/Alaskan Native | 0 | 1 (1.0) | 0 |
| Hispanic or Latino, No. (%) | 0 | 1 (1.0) | 1 (2.1) |
| Education, No. (%) | |||
| Less than college degree | 31 (32.3) | 33 (34.4) | 12 (25.0) |
| Completed college or technical training | 59 (61.5) | 57 (59.4) | 31 (64.6) |
| Other/missing | 6 (6.3) | 6 (6.3) | 5 (10.4) |
| Married, No. (%) | 64 (66.7) | 62 (64.6) | 31 (64.6) |
| BMI, mean (SD) | 30.8 (5.3) | 31.1 (6.3) | 31.5 (5.1) |
| No. of comorbidities, mean (SD) | 4.3 (2.0) | 4.4 (1.7) | 4.6 (1.9) |
| Type of comorbidity, No. (%) | |||
| Musculoskeletal | 96 (100) | 96 (100) | 48 (100) |
| Hypertension | 55 (57.3) | 67 (69.8) | 33 (68.8) |
| Eyes, ear, nose, throat, larynx | 39 (40.6) | 43 (44.8) | 25 (52.1) |
| Cardiac | 26 (27.1) | 33 (34.4) | 18 (37.5) |
| Upper gastrointestinal | 29 (30.2) | 28 (29.2) | 19 (39.6) |
| Other genitourinary | 27 (28.1) | 25 (26.0) | 13 (27.1) |
| Respiratory | 28 (29.2) | 25 (26.0) | 12 (25.0) |
| Psychiatric/behavioral | 30 (31.3) | 16 (16.7) | 12 (25.0) |
| Endocrine/metabolic | 18 (18.8) | 24 (25.0) | 14 (29.2) |
| Vascular | 19 (19.8) | 24 (25.0) | 11 (22.9) |
| Reason for TKR, No. (%) | |||
| Osteoarthritis | 92 (95.8) | 92 (95.8) | 48 (100) |
| Inflammatory arthritis | 4 (4.2) | 4 (4.2) | 0 |
| Time since surgery, mean (SD), d | 124 (26) | 124 (26) | 127 (25) |
| Surgical knee flexion, mean (SD), degrees | 124 (11) | 123 (11) | 124 (10) |
| Pain in surgical knee, mean (SD) | 2.7 (2.1) | 2.3 (1.7) | 2.2 (1.8) |
| Pain in nonsurgical knee, mean (SD) | 1.7 (2.0) | 1.4 (1.7) | 1.4 (2.0) |
Abbreviations: BMI, body mass index (calculated as weight in kilograms divided by height in meters squared); TKR, total knee replacement.
Race and ethnicity were self-reported by participants.
Measured by the Cumulative Illness Rating Scale.[44] Conditions with at least 20% prevalence are described.
Measured by an 11-point numeric pain scale ranging from 0 (no pain) to 10 (extremely intense pain).
Physical Function and Physical Activity Outcomes Over Time in Study Arms
| Outcome | No. | Physical Therapy, Mean (SD) | No. | Community, Mean (SD) | No. | Control, Mean (SD) | Arm | Mean Difference (CI) | ||
|---|---|---|---|---|---|---|---|---|---|---|
| Physical Therapy vs Control | Community vs Control | Physical Therapy vs Community | ||||||||
| Patient reported using the WOMAC-PF (primary) | ||||||||||
| Baseline | 96 | 20.9 (7.9) | 96 | 20.4 (7.4) | 48 | 20.2 (7.9) | NA | NA | NA | NA |
| 3 mo | 90 | 10.1 (6.6) | 87 | 12.2 (7.9) | 44 | 11.9 (7.6) | .04 | −2.1 (−4.9 to 0.7) | 0.1 (−2.7 to 2.9) | −2.2 (−4.5 to 0.1) |
| 6 mo | 89 | 9.8 (7.2) | 88 | 10.8 (7.9) | 45 | 11.8 (7.5) | .16 | −2.1 (−5.0 to 0.7) | −0.8 (−3.7 to 2.0) | −1.3 (−3.6 to 1.0) |
| Performance-based test scores combined by a composite score, | ||||||||||
| Baseline | 96 | 0.0 (0.8) | 96 | −0.1 (0.8) | 48 | −0.1 (0.7) | NA | NA | NA | NA |
| 3 mo | 89 | 0.5 (0.7) | 87 | 0.3 (0.8) | 44 | 0.1 (0.7) | <.001 | 0.3 (0.1 to 0.4) | 0.2 (0.0 to 0.3) | 0.1 (0.0 to 0.2) |
| 6 mo | 83 | 0.5 (0.8) | 76 | 0.4 (0.9) | 40 | 0.3 (0.7) | .04 | 0.2 (0.0 to 0.4) | 0.2 (−0.0 to 0.3) | 0.0 (−0.1 to 0.2) |
| Patient reported using the COPM-Performance | ||||||||||
| Baseline | 96 | 3.6 (1.3) | 96 | 3.8 (1.4) | 48 | 4.1 (1.3) | NA | NA | NA | NA |
| 3 mo | 90 | 6.5 (1.7) | 87 | 6.0 (1.8) | 44 | 5.4 (1.7) | <.001 | 1.3 (0.8 to 1.9) | 0.7 (0.2 to 1.3) | 0.6 (0.1 to 1.0) |
| 6 mo | 89 | 6.8 (1.9) | 88 | 6.6 (1.9) | 45 | 6.0 (1.6) | .04 | 1.0 (0.4 to 1.6) | 0.7 (0.1 to 1.2) | 0.3 (−0.1 to 0.8) |
| Patient reported using the COPM-Satisfaction | ||||||||||
| Baseline | 96 | 3.0 (1.5) | 96 | 3.3 (1.6) | 48 | 3.2 (1.7) | NA | NA | NA | NA |
| 3 mo | 90 | 6.6 (1.8) | 87 | 5.7 (2.1) | 44 | 5.0 (2.0) | <.001 | 1.7 (1.1 to 2.4) | 0.7 (0.1 to 1.4) | 1.0 (0.5 to 1.5) |
| 6 mo | 89 | 6.8 (2.1) | 88 | 6.5 (2.1) | 45 | 5.7 (1.9) | <.01 | 1.3 (0.6 to 2.0) | 0.8 (0.1 to 1.5) | 0.4 (−0.1 to 1.0) |
| Patient reported using the PROMIS-PF | ||||||||||
| Baseline | 96 | 42 (5) | 96 | 42 (5) | 48 | 43 (5) | NA | NA | NA | NA |
| 3 mo | 89 | 45 (5) | 86 | 45 (5) | 43 | 45 (5) | .34 | 1.0 (−0.4 to 2.5) | 0.5 (−1.0 to 1.9) | 0.6 (−0.6 to 1.7) |
| 6 mo | 89 | 45 (5) | 84 | 45 (5) | 45 | 44 (5) | .02 | 2.1 (0.7 to 3.6) | 1.4 (−0.1 to 2.9) | 0.8 (−0.4 to 2.0) |
| Patient reported using the RAND 36-PCS | ||||||||||
| Baseline | 96 | 38 (7) | 96 | 41 (7) | 48 | 40 (8) | NA | NA | NA | NA |
| 3 mo | 90 | 45 (9) | 87 | 45 (8) | 44 | 44 (8) | .13 | 2.3 (−0.2 to 4.7) | 0.7 (−1.8 to 3.2) | 1.6 (−0.4 to 3.6) |
| 6 mo | 89 | 46 (9) | 88 | 45 (9) | 45 | 44 (10) | .03 | 3.4 (0.5 to 6.2) | 0.9 (−2.0 to 3.7) | 2.5 (0.2 to 4.8) |
| Measured by a portable accelerometer, kcal/d | ||||||||||
| Baseline | 96 | 511 (411) | 95 | 541 (419) | 47 | 459 (352) | NA | NA | NA | NA |
| 3 mo | 85 | 566 (451) | 86 | 547 (407) | 43 | 525 (411) | .91 | 4 (−106 to 114) | −15 (−125 to 95) | 19 (−71 to 109) |
| 6 mo | 85 | 538 (403) | 80 | 480 (420) | 40 | 509 (518) | .61 | 15 (−112 to 142) | −36 (−164 to 92) | 51 (−52 to 154) |
| Patient reported using the CHAMPS, kcal/wk | ||||||||||
| Baseline | 96 | 4125 (2954) | 96 | 3840 (3124) | 48 | 3448 (2793) | NA | NA | NA | NA |
| 3 mo | 90 | 4489 (2907) | 87 | 4791 (3539) | 44 | 3765 (2896) | .35 | 305 (−615 to 1224) | 659 (−265 to 1583) | −355 (−1105 to 396) |
| 6 mo | 89 | 3956 (2695) | 88 | 4781 (3739) | 45 | 3540 (2724) | .03 | −33 (−939 to 872) | 896 (−11 to 1803) | −930 (−1672 to 188) |
Abbreviations: CHAMPS, Community Healthy Activities Model Program for Seniors questionnaire; COPM, Canadian Occupational Performance Measure; NA, not applicable; PROMIS-PF, Patient-Reported Outcomes Measurement Information System–Physical Function; RAND 36-PCS, RAND 36-Item Health Survey Physical Component Scores; WOMAC-PF, Western Ontario and McMaster Universities Osteoarthritis Index–Physical Function.
The means (SDs) of outcomes in study arms at each time point are based on complete cases. The results from the statistical tests and mean differences (CIs) for contrasts between arms are based on linear mixed models and include all participants originally randomized to each arm. The models are adjusted by age, sex, body mass index, surgical knee flexion, and baseline outcome. The CIs for the WOMAC-PF and z scores of functional performance represent 98.3% CIs. For the other outcome measures, the CIs represent 95% CIs.
The WOMAC-PF consists of 17 items scored on a 5-point Likert-type scale (version LK3.1). Scores of each item are summed, for a maximum total score of 68. Higher scores indicate worse functional limitations.[15]
Composite z score formed with unit-weighted z scores of the following 6 performance-based tests: 6-min walk, 40-m gait speed, stair ascend/descend test, single-leg stance balance, chair rise, and floor sitting and rising.[20,21,22,23,24] Higher z scores represent better functional performance. The z scores for each participant can be interpreted as deviations from the baseline mean of the whole group (eg, a change in z score of 0.1 represents approximately 10% of an SD relative to the baseline mean of the whole group).
The t statistics range from 30 to 70. Higher scores represent better physical function.[27]
Scores range from 0 to 100, with higher scores representing better physical health.[28]
In the COPM, the patients identify up to 5 activities that are limited, and performance and satisfaction are quantified (0-10 scale).[26] For COPM-Performance and COPM-Satisfaction, scores are the mean across activities and range from 0 to 10 (higher scores represent better performance and satisfaction). The same activities identified during baseline were used for follow-ups.
Estimated as energy expenditure during light-intensity activities or above (≥1.5 metabolic equivalent tasks) to account for intensity and time of activities.
Figure 2. Responder Analysis With Percentage of Responders by Arm for Each Definition of Treatment Response
A, Response defined as a rate of at least moderately better in patient global assessment of change in health status. B, Response defined as more than 20% improvement in both the Western Ontario and McMaster Universities Osteoarthritis Index–Physical Function (WOMAC-PF) and at least 3 of 6 tests of performance. C, Response defined as more than 50% improvement in the WOMAC-PF, more than 20% improvement in at least 2 of 6 tests of performance, and a rate of at least somewhat better in patient global assessment of change in health status.
aP < .05 for between-arm contrast at 3 and 6 months.
bP < .05 for between-arm contrast at 3 months.
Adverse Events, Cointerventions, and Adherence
| Variable | No. (%) | |||
|---|---|---|---|---|
| Physical Therapy (n = 96) | Community (n = 96) | Control (n = 48) | ||
| Related to study participation | ||||
| Arthralgia | 12 (12.5) | 7 (7.3) | 1 (2.1) | .10 |
| Back pain | 1 (1.0) | 2 (2.1) | 0 | .81 |
| Fall | 0 | 1 (1.0) | 1 (2.1) | .68 |
| Myalgia | 0 | 1 (1.0) | 0 | >.99 |
| Other musculoskeletal and connective tissue | 5 (5.2) | 0 | 0 | .03 |
| Skin and subcutaneous tissue | 1 (1.0) | 0 | 0 | >.99 |
| Related to study participation, severity greater than mild | ||||
| Arthralgia | 10 (10.4) | 6 (6.3) | 1 (2.1) | .01 |
| Back pain | 1 (1.0) | 2 (2.1) | 0 | .81 |
| Other musculoskeletal and connective tissue | 2 (2.1) | 0 | 0 | .36 |
| Related or not to study participation with >5% in a single arm | ||||
| Arthralgia | 18 (18.8) | 17 (17.7) | 8 (16.7) | .95 |
| Back pain | 7 (7.3) | 9 (9.4) | 5 (10.4) | .84 |
| Other musculoskeletal and connective tissue | 13 (13.5) | 13 (13.5) | 6 (12.5) | >.99 |
| Cataract | 1 (1.0) | 3 (3.1) | 3 (6.3) | .21 |
| Fall | 4 (4.2) | 4 (4.2) | 2 (4.2) | >.99 |
| Related or not to study participation with >5% in a single arm, severity greater than mild | ||||
| Arthralgia | 15 (15.6) | 15 (15.6) | 8 (16.7) | .98 |
| Back pain | 5 (5.2) | 8 (8.3) | 2 (4.2) | .65 |
| Other musculoskeletal and connective tissue | 8 (8.3) | 7 (7.3) | 6 (12.5) | .63 |
| Cataract | 1 (1.0) | 3 (3.1) | 3 (6.3) | .21 |
| Fall | 3 (3.1) | 2 (2.1) | 1 (2.1) | >.99 |
| TKR in the other knee | 2 (2.1) | 2 (2.1) | 0 | .69 |
| TKR revision | 0 | 0 | 0 | NA |
| Total hip replacement | 0 | 0 | 1 (2.1) | .20 |
| Sought health professional for knee pain | 16 (16.7) | 24 (25.0) | 8 (16.7) | .29 |
| Sought health professional for pain elsewhere | 31 (32.3) | 27 (28.1) | 14 (29.2) | .81 |
| Engaged in substantial exercise outside the study | 21 (21.9) | 18 (18.8) | 21 (43.8) | .005 |
Abbreviations: NA, not applicable; TKR, total knee replacement.
Falls are reported regardless of less than 5% occurrence because it was a prespecified adverse event.
Defined as participation in exercise of moderate intensity for 30 minutes at least 2 times per week.